Dysregulation of copper and zinc homeostasis in the brain plays a critical role in Alzheimer disease (AD). Copper binding to amyloid- peptide (A) is linked with the neurotoxicity of Aand free radical damage. Metallothionein-3 (MT-3) is a small cysteine-and metal-rich protein expressed in the brain and found down-regulated in AD. This protein occurs intra-and extracellularly, and it plays an important role in the metabolism of zinc and copper. In cell cultures Zn 7 MT-3, by an unknown mechanism, protects neurons from the toxicity of A. We have, therefore, used a range of complementary spectroscopic and biochemical methods to characterize the interaction of Zn 7 MT-3 with free Cu 2؉ ions. We show that Zn 7 MT-3 scavenges free Cu Essential transition metals like copper and zinc play a critical role in neurobiology. The homeostasis of both metals is tightly regulated and essential for brain physiology (1). In vitro evidence suggests that in physiological conditions micromolar concentrations of zinc and copper are actively released from neurons during neurotransmission processes into pre-and postsynaptic clefts. However, at present it is not known whether the released copper is present in a chemically exchangeable form (2). Dysregulated metal metabolism (zinc and copper) occurs in neurodegenerative disorders such as Alzheimer (3, 4), Parkinson (5), and prion (6) diseases. In these diseases increased extracellular copper concentrations and free-radical production have been found. There is now direct evidence that copper is bound to amyloid- peptide (A) 2 in senile plaque of Alzheimer disease (AD) (7). Copper is also linked with the neurotoxicity of A and free radical damage (8).Because of its redox-active nature (Cu ϩ /Cu 2ϩ ), its reactivity with molecular oxygen (O 2 ) generates the reactive oxygen species (ROS) such as superoxide, hydrogen peroxide, and hydroxyl radicals (9, 10). The redox cycling of copper requires its reduction by biological components, including ascorbate, which actively accumulates in the brain at concentrations between 0.5 and 10 mM (11). Hence, copper chelation and its redox-silencing may represent critical events in preventing the progression of neurodegenerative diseases. In recent years a metal chelation therapy has emerged as a promising tool to attenuate abnormal metal-protein interactions that lead to increased free-radical toxicity (10).The natural metal chelator metallothionein-3 (MT-3), also known as the growth inhibitory factor, is a small non-inducible cysteine-and metal-rich protein mainly expressed in the brain. In the brain its expression was found in zinc-enriched neurons. Like other mammalian metallothioneins (MTs), MT-3 binds with a high affinity essential monovalent and divalent d 10 metal ions Cu(I) and Zn(II). Recently, the interaction of Zn 7 MT-3 with the small-GTPase Rab3a, which is strictly linked to the exo-endocytotic cycle of synaptic vesicles, has been demonstrated. It has been suggested that Zn 7 MT-3 actively participates in synaptic cycle of zinc vesicles...